FDA Calendar for Hana BioSciences (HNAB)

| Register (free)
Hana Biosciences, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing products for the foundation of cancer care. Its lead product candidate, Marqibo (vincristine sulfate liposomes injection), is a targeted Optisome encapsulated formulation product candidate, which is in the development for the treatment of acute lymphoblastic leukemia and lymphomas. The company?s product candidates also include Menadione Topical Lotion, a supportive care product candidate for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, a type of anti-cancer agent used in the treatment of cell lung cancer, pancreatic, colorectal, breast, and head and neck cancer; and Brakiva (topotecan liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of solid tumors, including small cell lung cancer and ovarian cancer. In addition, its development stage product consists of Alocrest (vinorelbine liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of solid tumors, such as non-small-cell lung cancer. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. The company was founded in 2002 and is based in South San Francisco, California.


Drug Pipeline

Drug NameType Of DrugFDA StatusDrug Phase
Marqibo Cancer UnknownPhase 2


Events

No future events listed at this time, please check back later.
2 past event(s) found. Click here to view them.

Add New Event

In order to write a comment you must first login.

Login or Register (for free!)

Add Event

$0.00
0
1/1/0001 12:00:00 AM

Sponsors

Other Links